Skip to main content

CORRECTION article

Front. Oncol., 12 April 2022
Sec. Cancer Metabolism
Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.874053
This article is part of the Research Topic Tumor Cell Metabolism and Autophagy as Therapeutic Targets View all 17 articles

Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma

This article is a correction to:

  1. Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma

    1. Read original article
Li Che&#x;Li Che1†Panagiotis Paliogiannis&#x;Panagiotis Paliogiannis2†Antonio CiglianoAntonio Cigliano3Maria G. PiloMaria G. Pilo2Xin Chen*Xin Chen1*Diego F. Calvisi*Diego F. Calvisi2*
  • 1Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, San Francisco, CA, United States
  • 2Department of Medical, Surgical and Experimental Medicine, University of Sassari, Sassari, Italy
  • 3Institut für Pathologie, Universität Regensburg, Regensburg, Germany

A Corrigendum on:
Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma

By Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X and Calvisi DF (2019). Front. Oncol. 9:1412. doi: 10.3389/fonc.2019.01412

In the original article, there was a mistake in Figure 3 as published. Specifically the structure of Orlistat was incorrect. The corrected Figure 3 appears below.

FIGURE 3
www.frontiersin.org

Figure 3 Chemical structures of the main FASN inhibitors tested in preclinical and clinical studies.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hepatocellular carcinoma, de novo lipogenesis, FASN, tumor metabolism, precision medicine

Citation: Che L, Paliogiannis P, Cigliano A, Pilo MG, Chen X and Calvisi DF (2022) Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma. Front. Oncol. 12:874053. doi: 10.3389/fonc.2022.874053

Received: 11 February 2022; Accepted: 24 March 2022;
Published: 12 April 2022.

Edited and reviewed by:

Carlos Pérez-Plasencia, National Autonomous University of Mexico, Mexico

Copyright © 2022 Che, Paliogiannis, Cigliano, Pilo, Chen and Calvisi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xin Chen, xin.chen@ucsf.edu; Diego F. Calvisi, calvisid@uniss.it

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.